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Background: Adrenocortical carcinoma (ACC) is a rare tumor entity with restricted
therapeutic opportunities. HSP90 (Heat Shock Protein 90) chaperone activity is
fundamental for cell survival and contributes to different oncogenic signaling pathways.
Indeed, agents targeting HSP90 function have shown therapeutic efficacy in several
cancer types. We have examined the expression of HSP90 in different adrenal tumors
and evaluated the use of HSP90 inhibitors in vitro as possible therapy for ACC.
Methods: Immunohistochemical expression of HSP90 isoforms was investigated in
different adrenocortical tumors and associated with clinical features. Additionally, a
panel of N-terminal (17-allylamino-17-demethoxygeldanamycin (17-AAG), luminespib,
and ganetespib) and C-terminal (novobiocin and silibinin) HSP90 inhibitors were tested
on various ACC cell lines.
Results: Within adrenocortical tumors, ACC samples exhibited the highest expression
of HSP90β. Within a cohort of ACC patients, HSP90β expression levels were inversely
correlated with recurrence-free and overall survival. In functional assays, among five
different compounds tested luminespib and ganetespib induced a significant decrease
in cell viability in single as well as in combined treatments with compounds of the
clinically used EDP-M scheme (etoposide, doxorubicin, cisplatin, mitotane). Inhibition of
cell viability correlated furthermore with a decrease in proliferation, in cell migration and
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an increase in apoptosis. Moreover, analysis of cancer pathways indicated a modulation
of the ERK1/2—and AKT—pathways by luminespib and ganetespib treatment.
Conclusions: Our findings emphasize HSP90 as a marker with prognostic impact and
promising target with N-terminal HSP90 inhibitors as drugs with potential therapeutic
efficacy toward ACC.
Keywords: adrenal gland, cortisol, N-terminal HSP90 inhibitors, C-terminal HSP90 inhibitors, prognostic marker
INTRODUCTION
Adrenocortical carcinoma (ACC) represents a rare tumor
entity with variable but overall poor clinical outcome (1, 2).
Morbidity and mortality are defined by local space occupying
and infiltrating effects of the primary tumor, by metastatic
spread to distant organs and by the excessive secretion of
steroid hormones that result in Cushing’s syndrome and/or
hyperandrogenism. Despite recent progress in the understanding
of molecular mechanisms contributing to tumor growth and
the identification of genomic markers with prognostic value
(3, 4), it has not yet been translated into novel therapeutic
approaches. In fact, clinical studies evaluating targeted molecular
therapies have been mostly disappointing, including one placebo
controlled trial on inhibition of IGF2 dependent signaling (5).
Further targets that have been identified as affected by point
mutations, chromosomal alterations or epigenetic mechanisms
including p53/Rb or the Wnt/β-catenin dependent signaling
still lack suitable pharmacological approaches. As a result,
medical treatment of ACC patients not amendable to surgical
resection has barely changed over the last decade (6). Current
standard therapeutic regiments include doxorubicin, etoposide
and cisplatin (EDP) in combination with the adrenolytic
substance mitotane (7). However, the protocol carries a high
burden of toxic side effects and remains to be associated with
poor overall survival.
Heat shock proteins (HSPs) comprise a family of evolutionary
conserved molecules that are essential to protect cells against
stressor events and during growth conditions (8). HSPs generally
exert chaperoning functions, stabilizing unfolded precursor
proteins or the resolution of protein aggregates by direct binding
and ATP-dependent mechanisms (8).
Among these, HSP90 has emerged as a pivotal factor for
the survival of cancer cells. The protein is mostly located in
the cytoplasm, with about 5–10% localized in the nucleus.
While its cytoplasmic role is mainly ascribed to stabilization
of client proteins, its nuclear fraction was described to drive
nuclear transport of proteins like hormone receptors and protein
kinases (9, 10). There are two major isoforms of HSP90 in
vertebrates, HSP90α, and HSP90β, whether minor forms, such
as HSP90N and a mitochondrial isoform are reported (9,
11, 12). HSP90 is mainly formed by constitutive homodimers
dimers, but monomers (especially for HSP90β) or heterodimers
and higher oligomers of both isoforms may also be present.
HSP90α is described as strongly inducible by sources of cellular
stress such as heat shock and overexpressed in cancerous
cells, whether the HSP90β is constitutively expressed in most
tissues and much lesser inducible (12–14). Unlike the difficult
separation of the two isoforms and the absence of differentiation
between HSP90α and HSP90β in most functional studies (12),
considerable evidences were reported about their respective
biochemical function. Treatment of Zebrafish embryos with the
N-terminal HSP90 inhibitor Geldanamycin exhibited differential
effects in tissues expressing one or the other gene during
muscle differentiation (15). Yamada et al. described a possible
differential impact of HSP90α or β isoform overexpression in
the differentiation of human embryonal carcinoma cells (16).
HSP90β was shown to potentially play a role in different stages
of embryonic development (13, 17–19) and was shown to bind
to tubulin and actin with higher frequency than HSP90α and
other heat shock proteins, suggesting a role in cytoskeleton
structure organization (20). The general structure of the protein
homodimer is composed by a highly conserved amino-terminal
domain (NTD) connected to a middle domain (MD), followed
by a carboxy-terminal domain (CTD). The overall structure of
the NTD is an α/β sandwich with a pocket for a nucleotide-
binding site. The structures of the NTDs with nucleotide
bound confirmed that HSP90 is an ATP-binding protein with
ATPase activity (21). This evidence was confirmed by subsequent
mutagenesis studies and studies of HSP90 crystal structure with
natural HSP90 inhibitors proved their nucleotide-mimicry effect
for inhibition of ATPase activity (22, 23).
The structure of MD comprises two structural subdomains—
a large α/β/α domain linked to a smaller α/β/α domain (21, 24).
Although the catalytic center of HSP90 is in the NTD of the
protein, some evidences suggested an additional role by MD of
the protein to regulate bind, chaperoning, and release of client
proteins (25, 26).
The CTD is a homodimer of two small mixed α/β domains,
where the dimer interface is formed by two α-helices which pack
together to form a four-helical bundle (27, 28). This domain
plays a fundamental role in the conformational change of HSP90
to favor its dimerization (29). Analysis of a series of truncation
mutants of HSP90 showed that different regions at the CTD were
involved in trapping the bound ATP tomaximize hydrolysis rates
leading to a repositioning of both NTD and CTD (30). HSP NTD
and CTD are the principal targets of specific inhibitors that were
discovered or synthetized over the last two decades.
The breakthrough for the druggability of HSP90 was found
by the discovery of the target of the natural compounds
geldanamycin and radicicol (31, 32). Both drugs act by
selective inhibition of ATP binding and hydrolysis, with
the consequent degradation of oncogenic clients (33–35).
Subsequent improvements of these molecules—such as the
Frontiers in Endocrinology | www.frontiersin.org 2 July 2019 | Volume 10 | Article 487
Siebert et al. HSP90 Inhibition in Adrenocortical Cancer
better-tolerated geldanamycin analog 17-allylamino-17-
demethoxygeldanamycin (tanespimycin, 17-AAG)—could reach
clinical-trial use but showed limited solubility and liver toxicity
(36, 37). HSP90 CTD has also been investigated for its suitability
to be targeted by pharmacological agents. Coumarin antibiotics,
such as novobiocin, and an extract frommilk thistle seeds named
silibinin showed the ability to induce apoptosis in cancer cells, in
some cases with superior efficacy compared with tanespimycin
(38). Noteworthy, silibinin treatment led to a release of mature
glucocorticoid receptor (GR) from the chaperoning complex,
partially restoring glucocorticoid sensitivity in an allograft
model for Cushing’s disease (39). Subsequent efforts testing
diverse chemical scaffolds led to the development of highly
potent, second-generation, small molecule HSP90 inhibitors
with improved pharmacological properties and safety profiles.
This is the case of the N-terminal inhibitors luminespib and
ganetespib, which lack the hepatoxicity noted for the first-
generation inhibitors due to the absence of the benzoquinone
moiety in their structure (40, 41). Both compounds showed
potent preclinical efficacy in a wide range of tumor types for
instance in lung and prostate cancer and reached phase II and
phase III studies, respectively1 (42, 43).
In the current study, we make usage of a large patient
collection to evaluate the expression of HSP90 as a potential
prognostic marker and therapeutic target. We further aimed
to translate these clinical data in suitable in vitro models to
substantiate initial findings and to identify underlying molecular
mechanism that follows targeting of specific HSP90 domains.
Thereby, we present evidence that specific N-terminal HSP90
inhibitors could provide promising treatment opportunities for
ACC patients that could be tested in future clinical studies.
MATERIALS AND METHODS
Patient Cohorts
Two groups of patients with adrenocortical tumors were
included in the immunohistochemical analysis. Patient group
1 consisted of 32 patients with adrenal tumors: eight patients
with nonfunctional adenomas (NFA), 18 patients with cortisol-
secreting adenomas [four patients with autonomous cortisol
secretion without signs of overt Cushing (ACS) and 14 patients
with overt Cushing’s syndrome (CS)] and six patients with
adrenocortical carcinoma (ACC). All of those were diagnosed
and surgically treated at one referral center (Klinikum der
Ludwig-Maximilians-Universität München, Munich, Germany).
Patient group 2 was comprised of a cohort of 80 ACC patients
from six European centers. Diagnostic work-up was done
following established criteria based on clinical, biochemical,
and morphological data according to recent ESE/ENSAT
guidelines (44, 45). Clinical data were collected through the
ENSAT database2. All patients had provided written informed
consent and the study was approved by ethics committees
1https://clinicaltrials.gov/ct2/results?term=AUY-922&age_v=&gndr=&type=&
rslt=With&phase=1&phase=2&Search=Apply; https://clinicaltrials.gov/ct2/
results?term=ganetespib&age_v=&gndr=&type=&rslt=With&Search=Apply
2www.ensat.org
at all participating institutions (Medizinische Fakultät der
Universität München, Maastrich University, Hôpital Cochin
Paris, University of Florence, and Universität Würzburg).
Immunohistochemistry and Quantification
Archival tumor blocks from patient group 1 were sectioned
following standard procedures. For patient group 2, tissue
microarrays were constructed by sampling three tumor tissue
cores (1.0mm in diameter) from each paraffin-embedded tissue
block, which were selected based on representative hematoxylin-
eosin stained tissue sections. The construction of the tissue
microarrays was performed on an automated TMA constructor
(ATA-27; Beecher Instruments, Sun Prairie, WI) available at the
Department of Pathology, Erasmus MC, as previously described
(46). Tumor samples were deparaffinized and microwaved in
100mM Tris-HCl pH 8.0, 10mM EDTA for antigen retrieval.
Non-specific background was blocked by incubation with 0.03
v/v H2O2 in methanol for 10min. and with 0.2 v/v human
AB serum (Merck, Darmstadt, Germany) in 100mM Tris-HCl
pH 7.6, 0.001 v/v Tween R© 20 for 1 h at RT. The proteins
of interests were detected using primary antibodies specifically
directed against human HSP90α/β (1:300 in blocking buffer,
clone ERP3953, Abcam, Cambridge, UK), HSP90β (1:750,
E296, Abcam, Cambridge, UK) and stained using the EnVision
Detection System (DAKO-Kit, Santa Clara, United States).
For further immunohistochemical studies, tumor blocks from
xenografted MUC-1 and NCI-H295R cells were utilized. For
NCI-H295R (47), 15 × 106 cells in a volume of 200 µl PBS had
been inoculated into female athymic NMRI nu/nu mice, while
for MUC-1 (48), the originally established xenograft from patient
material had been repeatedly passed over into other groups
of animals. Immunohistochemical staining of NCI-H295R and
MUC-1 xenograft tissues was performed as described above
excepted antigen retrieval was conducted with 10mM citrate
buffer pH = 6.0 for HSP90α/β and non-specific background
was blocked with 0.01 v/v H2O2 in methanol. Xenograft tissues
were counter-stained with Harris Hematoxylin (Sigma-Aldrich).
Slides were dehydrated and mounted with Roti R©-Histokitt II
(Roth, Karlsruhe, Germany) and pictures were taken by optical
microscope Leica DMRB and a Leica DMC 2900 digital camera
(Leica, Wetzlar, Germany).
For patient group 1, levels of HSP90α/β and HSP90β
were evaluated by means of a semi-quantitative H-score
with four categories (0 no immunoreactivity, 1 low
immunoreactivity, 2 intermediate immunoreactivity, and 3
high immunoreactivity) followed by calculation of individual
scores for each high power field image using the formula
H = n0∗0+n1∗1+n2∗2+n3∗3/(3∗n), where n refers to the
number of counted cells and calculation of the average H-score
for 10 representative high power fields. For patient group 2,
stained tissue microarray slides were scanned at ×20 objective
magnification using a digital Mirax Desk slide scanner (Carl
Zeiss Microscopy GmbH, Jena, Germany) and analyzed with the
image analysis software Definiens Developer XD2 (Definiens
AG, Munich, Germany), as previously described (49). Tumor
areas were annotated manually, and a setup of rules was defined
to detect and quantify staining intensities in the annotated tumor
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area, with operators blinded with regard to corresponding in
vivo steroid output.
Cell Culture and Primary Culture
Two human adrenocortical carcinoma cell lines were used for
these experiments, NCI-H295R cells (ATCC) and the newly
developed MUC-1 cell line (48). NCI-H295R cells were cultured
in RPMI (1640) plus GlutaMAX (Thermo Fisher Scientific
Gibco, Waltham, MA, USA) supplemented with 0.1 v/v fetal
bovine serum (FBS, Thermo Fisher Scientific Gibco), 0.01
v/v, penicillin/streptomycin (Thermo Fisher Scientific Gibco)
and 0.01 v/v insulin-transferrin-selenium (ITS, Thermo Fisher
Scientific Gibco). The culture medium of MUC-1 was advanced
DMEM/F12 (Thermo Fisher Scientific Gibco), containing 0.1 v/v
FBS and 0.01 v/v penicillin/streptomycin. The treatment medium
of MUC-1 cells was DMEM/F12 (Thermo Fisher Scientific
Gibco) containing 0.02 v/v charcoal stripped serum (Thermo
Fisher Scientific Gibco) and 0.01 v/v penicillin/streptomycin.
For NCI-H295R further 0.01 v/v ITS and 0.01 v/v glutamine
were added.
For primary culture, we utilized samples of metastases
from a 32-year-old female with a history of an androgen
and cortisol producing ACC. Upon pathological examination,
surgical tumor samples were cleaned from fat and connective
tissues followed by separation in small pieces and centrifugation
at 1100 rpm for 5min. Upon removal of collagen and
erythrocytes, cells were separated from larger tumor pieces.
Finally, cells were seeded in RPMI (1640) plus GlutaMAX, 0.1
v/v fetal calf serum (FCS, Biochrom KG, Berlin, Germany),
0.01 v/v penicillin/streptomycin and 0.004 v/v amphotericin B
(Biochrom KG).
Immunofluorescence
NCI-H295R (1.5 × 105 to 1.8 × 105) and MUC-1 (8 × 104 to
1 × 105) cells were seeded in 4-well chamber slides (Sarstedt,
Nümbrecht, Germany) and incubated overnight. Afterwards,
cells were washed twice with PBS and fixed with 1 mL/well
with freshly prepared 0.04 v/v paraformaldehyde solution
for 30min. at RT. Following two washing steps with PBS,
immunofluorescence staining for HSP90α/β and HSP90β was
conducted according to the protocol for immunohistochemistry
except for the dehydration/rehydration steps and inhibition of
endogenous peroxidases. Alexa Fluor R©594 donkey-anti rabbit
(1:200, Cell Signaling, Cambridge, United Kingdom) was used as
secondary AB and slides were covered with Vectashild mounting
mediumwith DAPI (Vector Laboratories Inc. Burlingame, USA).
MUC-1 cells were stained with monoclonal antibodies specific
for ERK1/2 (1:100, Cell Signaling) and p-ERK1/2 (1:250,
Cell Signaling). The secondary AB Alexa Fluor R©488 donkey-
anti rabbit (1:200, Cell Signaling) was used and slides were
mounted as described before. Staining was documented using the
fluorescence microscope Leica DM2500 with a Leica DFC 340 FX
camera (Leica, Wetzlar, Germany).
Cell Viability
MTT assays were performed in a 96-well plate format. NCI-
H295R (5 × 103 per well) and MUC-1 (6 × 103 per well)
were seeded in 100 µL culture medium for single HSP90
inhibitor treatment in variable concentrations with ganetespib,
luminespib (both from Selleckchem, Houston, TX, USA), 17-
AAG (Tocris, Bristol, UK), silibinin (Sigma-Aldrich), and
novobiocin (Calbiochem, San Diego, United States), respectively.
For combined treatment (HSP90 inhibitor + compounds from
the EDP-M scheme) 8 × 103 NCI-H295R cells/ well and 6
× 103 MUC-1 cells/ well were seeded in 100 µL culture
medium. Following the individual incubation durations, medium
was removed and 0.5 mg/ mL MTT (Sigma-Aldrich) (100
µL/well) was added to the cells for 2 h. The reaction was
stopped by adding 0.1 v/v SDS (100 µL/ well). Absorbance
at λ = 570 nm and λ = 655 nm was measured in a TECAN
Sunrise
TM
absorbance reader (Männedorf, Switzerland) and an
iMarkTM microplate absorbance reader (Bio-Rad Laboratories
Inc., Hercules, United States).
Celltiter Blue assay (Promega, Mannheim, Germany) was
performed in 96-well plate format for primary culture cells.
ACC cells (2 × 103 per well, 100 µl/well) were seeded and
treated with 0.2µM luminespib and 0.2µM ganetespib for 72 h.
Afterwards Celltiter Blue assay was conducted following the
manufacturer’s instructions.
Cell Proliferation ELISA
5-bromo-2′-deoxyuridine (BrdU)
NCI-H295R (8 × 103 cells per well) and MUC-1 (6 ×
103 cells perwell) cells were treated with HSP90 inhibitors
(luminespib, ganetespib, 17-AAG, novobiocin and silibinin)
for 12 and 48 h, respectively. BrdU assay was performed using
cell proliferation ELISA (BrdU, colorimetric immunoassay)
(Roche, Basel, Switzerland) for quantification following
manufacturer’s instructions.
Apoptosis (Caspase-3/7 Assay)
NCI-H295R (8× 103 cells per well) andMUC-1 (8× 103 cells per
well) cells were seeded on 96-well-plates and incubated overnight
following incubation with the respective HSP90 inhibitors for
24 h. For quantification of caspase-3 and caspase-7 activity
the luminescent assay Caspase-Glo 3/7 (Promega, Madison,
Wisconsin, United State) was used following the manufacture’s
protocol with luminescence detection in a Victor 1420 multilabel
counter (PerkinElmer, Rodgau, Germany).
Cell Migration
Influence of HSP90 inhibitors on cell migration was determined
using the wound healing assay (ibidi GmbH, Martinsried,
Germany). Specifically, NCI-H295R (3.7 × 104 per chamber)
and MUC-1 (1 × 104 per chamber) cells were seeded and
incubated overnight. At the following day, cells were treated
with 0.005 v/v charcoal stripped serum media containing 0.01
v/v penicillin/streptomycin and HSP90 inhibitors (luminespib,
ganetespib, novobiocin, and silibinin). In addition, mitomycin
C (10µM, Roth GmbH & Co. KG, Karlsruhe, Germany) was
added to inhibit proliferation. Images were taken at different time
points (0, 9, 24, and 48 h) and cell-free area was quantified using
ImageJ Software.
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Immunoblotting
NCI-H295R and MUC-1 cell proteins were extracted in RIPA
buffer (50mMTris pH8.0, 150mMNaCl, 0.01 v/v NP-40 (Sigma-
Aldrich), 0.005 v/v sodium deoxycholate (Sigma-Aldrich), and
0.001 v/v SDS (Roth) supplemented with complete protease
inhibitor cocktail (Roche) and phosphatase inhibitor cocktail
(Sigma-Aldrich). The homogenized lysate was centrifuged at
16,000 g for 15min and protein concentration was quantified by
Bradford protein assay (Bio-Rad, Hercules, Ca, USA) following
the manufacturer’s recommendations. Twenty microgram of
protein solution was re-suspended in Roti-Load (Roth) loading
buffer and boiled for 5min at 95◦C. Sample separation was
done in a 0.1 v/v polyacrylamide gel and then transferred
onto a nitrocellulose membrane (Merck-Millipore, Kenilworth,
United States). After blocking in 0.05 v/v non-fat milk [diluted
in TBST (137mM NaCl, 2.7 nM KCl (Sigma-Aldrich), 19mM
TrisHCl, 0.1 % Tween R©20 (Sigma-Aldrich)] at RT for 1 h,
membranes were incubated overnight with primary antibodies,
following three washes for 5min. at RT and incubation for
1 h at RT with corresponding HRP-conjugated secondary anti-
mouse (7074S, 1:2000, Cell Signaling) or anti-rabbit (7076S,
1:2000, Cell Signaling), diluted in 0.05 v/v non-fat dry milk. After
three additional washes, proteins of interest were detected using
enhanced chemiluminescence (ECL) solution (Merck-Millipore)
in a Molecular Imager R© ChemiDoc
TM
XRS+ with Image Lab
TM
Software (Bio-Rad). The list of primary antibodies used in this
study is available on Table 1.
Cortisol Measurement
NCI-H295R (8 × 105 cells per well) were seeded in 6 well
plates and left overnight to recover. Treatment for 6 and 24 h
with HSP90 inhibitors was performed at the following day,
TABLE 1 | List of antibodies used for immunoblot analysis.
Target Size (KDa) Dilution Cat.No Manufacturer
AKT 60 1:2000 4,691 Cell signaling
p-Ser473 AKT 60 1:2000 9,271 Cell signaling
β-ACTIN 43 1:5000 MAB1501 Merck-millipore
ERK 1/2 42,44 1:4000 9,102 Cell signaling
p-ERK 1/2 42, 44 1:4000 9,101 Cell signaling
GR 91, 94 1:2000 12,041 Cell signaling
HSP90α 90 1:1000 PA3-013 Thermo fisher
HSP90β 90 1:1000 PA3-012 Thermo fisher
MEK 1/2 45 1:1000 9,122 Cell signaling
p-Ser217/221 MEK 1/2 45 1:1000 9,121 Cell signaling
c-Raf 65 to 75 1:1000 9,422 Cell signaling
p-Ser338-c-Raf 74 1:1000 9,427 Cell signaling
RAS 20 1:1000 3,965 Cell signaling
RSK 90 1:1000 9,355 Cell signaling
p-Ser380 RSK 90 1:1000 11,989 Cell signaling
mTOR 289 1:1000 2,972 Cell signaling
p-Ser2448 TOR 289 1:1000 2,971 Cell signaling
β-ACTIN was used as protein loading control.
supernatants were collected at each time point and cortisol
measurement was conducted by Liaison, Diasorin, Sallugia Italy.
Cell viability was quantified by MTT assay as described above.
Statistical Analysis
Semi-quantitative HSP90 immunostaining was correlated with
clinical parameters of patients from group 1 using the
Spearman’s rank correlation, Wilcoxon rank-sum test and
Kruskal-Wallis-Test. In addition, for patients from group 2,
HSP90 immunostaining was evaluated for differences in patient
survival determined using the Kaplan-Meier log-rank test.
Progression-free survival (PFS) was defined as time elapsed from
primary resection of ACC to the first recurrence of disease
while overall survival (OS) was defined as time elapsed from
primary resection of ACC to disease-related death or last follow-
up visit. Multivariate survival analysis was performed using Cox
proportional hazards regression models. All calculations were
performed using R version 3.4.3 with the survival package3.
For in vitro experiments, results were evaluated with
GraphPad Prism (Houston, TX, USA) and illustrated as mean
± SD. Statistical significance was determined using analysis
of variance (ANOVA) or Kruskal-Wallis-test, followed by
Bonferroni’s or Dunnett correction for multiple comparisons.
Synergy scores were calculated with web application4 using the
ZIP method (50).
Statistical significance was defined as P < 0.05 and denoted
as stars for the highest used concentration of HSP90 inhibitor
(∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001) in all
figures, if not stated otherwise.
RESULTS
HSP90 Immunostaining as a Prognostic
Marker of ACC
To explore the role of HSP90α/β and β as potential biomarkers
in adrenal tumors, their expression was evaluated by
immunohistochemistry in FFPE samples from patient group
1, which included 32 patients with non-functional adenomas
(NFA), adenomas associated with autonomous cortisol secretion
(ACS) and overt Cushing’s syndrome (CS) and ACC, respectively
(Supplemental Table 1A). Immunoreactivity was quantified
as H-scores. Expression levels for HSP90β were higher in
ACC samples (n = 6) in comparison to adenomas (CS, n =
14; SCS, n = 4; NFA, n = 8) (Figures 1A,B). In contrast, no
clear differences among the groups were evident for HSP90α/β
staining intensities.
For further analysis within ACC samples, cytoplasmic
intensities of HSP90α/β and β were quantified in a cohort of
80 ACC patients (patient group 2; Supplemental Table 1B)
using digital image analysis. Following correlation with clinical
characteristics, lower intensity of HSP90β was associated
with hormone-producing ACCs (Supplemental Figure 1).
On the other hand, there were no significant correlations
between cytoplasmic intensities of HSP90α/β and β and clinical
3https://github.com/therneau/survival
4https://synergyfinder.fimm.fi/
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FIGURE 1 | HSP90α/β and HSP90β staining in adrenocortical adenomas (NFA, non-functional adenoma, n = 8; ACS, adenoma with autonomous cortisol secretion,
n = 4; CS, adenoma with overt Cushing syndrome, n = 14) and adrenocortical carcinoma (ACC, n = 6) with representative sections (A) and semi-quantitative
H-scores (B). Representative images of HSP90α/β and HSP90β immunohistochemistry from an ACC patient with good prognosis without recurrence and one with
poor prognosis with disease related death, respectively (C). Kaplan-Meier plots for disease-free and overall survival (D) in relation to HSP90α/β and HSP90β
cytoplasmic intensity above (high: red line) or below (low: black line) the cut off. Log rank test was used to statistically compare the curves and P-values are provided
(*P < 0.05).
parameters such as age at diagnosis, Weiss score and Ki67
index (Supplemental Table 2). In addition, Cox proportional
hazards regression revealed a significant relationship between
low cytoplasmic intensities of HSP90β and disease-free survival
and overall survival, while no such correlation was observed
between cytoplasmic intensities of HSP90α/β (Figures 1C,D).
As expected, clinical factors such as age at diagnosis, cortisol
production and ENSAT stage were significantly correlated
with disease-free survival (Supplemental Table 3A) and overall
survival (Supplemental Table 3B). Similarly, Weiss scores
were associated with overall survival (Supplemental Table 3B).
Interestingly, multivariate analysis using clinical factors revealed
that low cytoplasmic HSP90β staining intensity remained an
independent factor for disease free survival (Table 2A), while
only cortisol production and ENSAT stage were significant for
overall survival (Table 2B). In addition, multivariate analysis
including Ki67 index and cytoplasmic intensities of HSP90β
showed that both factors were independent regarding disease
free survival (Supplemental Table 4A) and overall survival
(Supplemental Table 4B).
Abundance and Localization of HSP90α/β
and HSP90β Isoforms in ACC Xenografts
and ACC Cell Lines
Immunohistochemical analysis of HSP90α/β and HSP90β in
NCI-H295R andMUC-1 xenograft tissues demonstrated a higher
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abundance of both isoforms in MUC-1 xenografts compared to
those of NCI-H295R (Figure 2A). With respect to subcellular
distribution, immunofluorescence staining of NCI-H295R and
MUC-1 cells demonstrated both a nuclear and cytoplasmic
localization of HSP90α/β, while HSP90β was found to be
localized primarily in the cytoplasm (Figure 2B). Expression of
HSP90α, HSP90β and the glucocorticoid receptor (GR) were
further quantified by Western Blot analysis. In both cell lines,
treatment with either C- or N-terminal HSP90 inhibitors had
no effect on the expression of HSP90α and HSP90β. In contrast,
luminespib and ganetespib treatment resulted in a decrease of
GR expression in both cell lines (Figure 2C), as also described
for other cell lines (51).
TABLE 2 | Multivariate analysis using Cox proportional hazard ratio model for
disease free survival (A) and overall survival (B) (HR, hazard ratio; CI, confidence
interval).
A
Disease free survival
covariates
Cut off (category) HR 95%CI P-value
Age at diagnosis, years ≥61 (vs. <61) 1.507 0.648–3.502 0.341
Cortisol production Yes (vs. No) 2.248 1.139–4.435 0.020
ENSAT stage IV (vs. I, II, and III) 4.560 1.604–12.96 0.004
Cytoplasmic intensity of
HSP90β
<0.760(vs. ≥0.760) 2.574 1.183–5.598 0.017
B
Overall survival
covariates
Cut off (category) HR 95%CI P-value
Age at diagnosis, years ≥60 (vs. <60) 1.694 0.814–3.524 0.159
Cortisol production Yes (vs. No) 2.584 1.270–5.259 0.009
ENSAT stage IV (vs. I, II, and III) 7.676 3.314–17.78 <0.001
Cytoplasmic intensity of
Hsp90β
<0.760(vs. ≥0.760) 1.672 0.761–3.671 0.200
N-terminal HSP90 Inhibitors Display
Anti-tumor Efficacy as Single Agents
Against ACC Cells
To determine the anti-tumor effectiveness of N-terminal and
C-terminal HSP90 inhibitors, cell viability was investigated in
single and combined treatment protocols. Thereby, NCI-H295R
and MUC-1 cell viability was significantly affected in a time
and dosage dependent manner by single use of luminespib and
ganetespib while 17-AAG demonstrated significant effects only
in MUC-1 cells (Figures 3A,B).
To further provide insights whether the effects of HSP90
inhibitors on cellular viability are accompanied by inhibition
of cell growth, proliferation assays for both cell lines were
included in the analysis. In fact, luminespib and ganetespib
induced strong anti-proliferative effects in both cell lines after
48 h of treatment, but only MUC-1 cells responded to 17-AAG
as well (Figures 3A,B).
A further increase of apoptosis was observed by single use
of luminespib and ganetespib in NCI-H295R cells after 24 h of
treatment (Figure 3A). In variance with NCI-H295R cells, no
significant increase of apoptosis was identified upon luminespib
and ganetespib treatment in MUC-1 cells (Figure 3B).
Additionally, cell migration assays demonstrated strong
significant effects upon luminespib and ganetespib in NCI-
H295R (Figure 4A) and MUC-1 (Figure 4B) cells in comparison
to vehicle treatment. In contrast, C-terminal HSP90 inhibitors
were ineffective on cell migration compared to vehicle treated
cells (Figures 4A,B).
In summary, neither silibinin (S) nor novobiocin (N)
illustrated any effects toward cell viability, cell proliferation,
apoptosis or cell migration in any cell lines following the dosages
and timing of the current experimental conditions (Figure 4 and
Supplemental Figure 2). In contrast, the N-terminal inhibitors
luminespib and ganetespib were effective in both cell lines,
with more pronounced effects on the induction of apoptosis in
FIGURE 2 | Representative pictures of the abundance of HSP90α/β and HSP90β in NCI-H295R and MUC-1 xenografts (A). Immunofluorescence staining illustrating
the localization of HSP90α/β (a, g: DAPI; b,h: HSP90α/β; c,i: merged) and HSP90β (d,j: DAPI; e,k: HSP90β; f,l: merged) in NCI-H295R (a–f) and MUC-1 (g–l) cells (B).
Expression of HSP90α, HSP90β and glucocorticoid receptor (GR) was demonstrated by Western Blot analysis. NCI-H295R and MUC-1 cells were treated with
HSP90 inhibitors for 48 h vehicle (V): 1:1000 DMSO; luminespib (L): 0.2µM; ganetespib (G): 0.2µM; novobiocin (N): 100µM; silibinin (S): 40µM (C). Scale bars
represent 25µm.
Frontiers in Endocrinology | www.frontiersin.org 7 July 2019 | Volume 10 | Article 487
Siebert et al. HSP90 Inhibition in Adrenocortical Cancer
FIGURE 3 | Anti-tumor properties of N-terminal HSP90 inhibitors investigated in NCI-H295R (A) and MUC-1 (B) cells. Using different drug concentrations and
following different time points, efficacy on cell viability (upper panel), cell proliferation (middle panel), and apoptosis (lower panel) were quantified. Analysis were done in
triplicates and statistical analysis was performed using analysis of variance (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).
NCI-H295R cells and more relevant inhibition of proliferation in
MUC-1 cells, respectively.
Following the initial screening and in-depth characterization
of a range of HSP90 inhibitors, primary cultures from two
distinct metastatic sites (lung and diaphragm) of a patient
with stage IV ACC were treated for 72 h with 0.2µM
luminespib and ganetespib, respectively. HSP90 inhibitors
revealed significant treatment effects by luminespib and
ganetespib (Figure 5).
Determination of Combinatory Effects of
N-terminal HSP90 Inhibitors
Following the success of single treatment with luminespib and
ganetespib, we further explored whether additive or synergistic
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FIGURE 4 | Cell migration analysis at different time points and with different HSP90 inhibitors in NCI-H295R (A) and MUC-1 (B) cells. Treatment was performed in
presence of mitomycin C to avoid cell proliferation. Representative pictures of three independent experiments are shown and statistical analysis was performed using
analysis of variance. Scale bars represent 200µm (***P < 0.001; ****P < 0.0001).
FIGURE 5 | Anti-tumor effects of 0.2µM luminespib (L) and 0.2µM ganetespib (G) vs. vehicle (V) were analyzed in ACC primary culture cells of the same patient. The
illustrations demonstrate the effects on cell viability in lung and diaphragm metastasis. Measurements were performed with one ACC primary culture in quadruplicates
and statistical analysis was done using analysis of variance (****P < 0.0001).
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effects would be in concomitance with the standard EDP-M
scheme. In fact, relevant dosage and time dependent synergistic
effects were evident particularly following co-treatment with
doxorubicin and etoposide, respectively (Figures 6A,B). In
contrast, cisplatin and mitotane demonstrated weak additional
effects when used in combination with the different HSP90
inhibitors (ganetespib, luminespib, silibinin; novobiocin) in both
cell lines (data not shown).
Molecular Effects of HSP Inhibitors in
Adrenocortical Cancer Cell Lines
As demonstrated above, NCI-H295R cells were more sensitive
to single and combined treatment than MUC-1 cells (Figures 3,
6), and showed different response on cell proliferation and
apoptosis. To further elucidate those observations, we
investigated the effects of HSP inhibition on intracellular
pathways. Specifically, analysis of the ERK1/2 (extracellular-
regulated kinase 1/2) pathway indicated a decrease of p-cRAF
and p-MEK1/2 forms upon luminespib and ganetespib treatment
in both cell lines. Interestingly, a decrease of p-ERK1/2 and
further downstream targets of ERK1/2 pathway was observed
upon luminespib and ganetespib treatment only in MUC-1
cells. Immunofluorescence staining also proved significant
decrease of p-ERK1/2 in luminespib and ganetespib treated
MUC-1 cells (Figures 7B,C). In contrast, C-terminal HSP90
inhibitors were ineffective on ERK1/2 pathway in NCI-H295R
and MUC-1 cells (Figure 7A). Additionally, we investigated
the AKT-pathway. A decrease of p-AKT and p-mTOR was
demonstrated by the used N-terminal HSP90 inhibitors,
luminespib and ganetespib, in both adrenocortical carcinoma cell
lines (Figure 7A).
In conclusion, functional activity on cell lines as
assessed by cell viability is mirrored to some extent by
FIGURE 6 | Demonstration of efficacy of N-terminal HSP90 inhibitors (luminespib and ganetespib) in combination with compounds of the clinically used EDP-M
scheme on cell viability in NCI-H295R (A) and MUC-1 (B) cells. Effects are based on three independent experiments with bar charts and heatmaps using analysis of
variance, where red color indicates combined effects and green color provides indication of non-combined effects (*P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001).
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FIGURE 7 | Effects of HSP90 inhibition on ERK1/2 and AKT pathways were investigated in NCI-H295R and MUC-1 cells after 48 h treatment with HSP90 inhibitors
luminespib (L): 0.2µM, ganetespib (G): 0.2µM, novobiocin (N): 100µM, and silibinin (S) 40µM, vehicle (V): 1/1000 DMSO. Representative blots of two to three
independently experiments are shown (A). Representative immunofluorescence pictures of ERK1/2 and p-ERK1/2 demonstrated a significant reduction of ERK1/2
activation upon treatment with luminespib and ganetespib (B,C). V: 1:1000 DMSO 48h (a-d); L: 0.2µM 48h (e–h); G: 0.2µM 48h (i–l). Analysis of three pictures from
each staining and treatment was performed. Scale bars represent 25µm (*P < 0.05; **P < 0.01; ***P < 0.001).
molecular profiles in pathways known to have impact in
adrenocortical tumorigenesis.
Modulation of Steroidogenesis Upon
HSP90 Inhibitor Treatment
Significant reduction of cortisol secretion can be induced after
novobiocin, silibinin, and ganetespib treatment already at time
points when no relevant effects on cellular viability is observed.
Provided the low steroidogenic capacity of MUC-1 cells we have
restricted the experiments on NCI-H295R cells (Figure 8).
DISCUSSION
Herein we provide evidence that expression levels of isoforms of
HSP90 bear prognostic value in ACC patients and that targeting
HSP90 function has therapeutic potential resulting in consistent
anti-tumor effects in different cell systems of adrenocortical
cancer origin.
Specifically, we demonstrate that HSP90β expression
is significantly higher in ACC in comparison to benign
adrenocortical adenomas independently of their endocrine
activity, while HSP90α/β is more evenly distributed among these
tumor entities. These results confirm the general observation
that HSP90 is produced at a higher level in cancer cells (52). It is
interesting to note, however, that within the group of ACCs, the
more malignant phenotype was associated with lower HSP90β
expression, which translates into a decrease in recurrence-free
and overall survival. This association was maintained even in
multivariate analysis providing indirect evidence for a functional
impact of this feature on tumor biology. In contrast, HSP90α/β
expression has no relevant prognostic impact.
Over the last decade, it has become increasingly clear
that ACC—similar to other tumor entities—comprise a
heterogeneous group of tumors that differ in their genetic
and molecular set-up, hormonal capacity and malignant
behavior. A number of immunohistochemical markers have been
identified that are associated with prognostic value. However,
in many instances it remains uncertain whether the difference
in expression levels is in causal relationship with the clinical
characteristics or caused by other molecular events. As for the
lower expression of HSP90β it remains to be shown in functional
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FIGURE 8 | NCI-H295R demonstrated significant reduction of cortisol secretion after 6 and 24 h treatment with HSP90 inhibitors. Analysis were done in triplicates and
statistical analysis was performed using analysis of variance (*P < 0.05; **P < 0.01; ****P < 0.0001).
studies whether this finding is cause or consequence of malignant
clinical characteristics.
Considering the limited treatment opportunities for ACC
patients, there is a continuous need to explore new therapeutic
modalities in a therapeutic setting. HSP inhibition has recently
been postulated as a promising avenue for targeting of ACC (53,
54). Our current data provide in vitro evidence for a potential use
of HSP inhibitors in the treatment of ACC patients. Specifically,
we show that later generation N-terminal HSP90 inhibitors,
such as luminespib and ganetespib, display strong anti-tumor
activity with effects on cell viability, cell proliferation, cellular
migration, and to a lesser extent on apoptosis. For potential
clinical applications, these substances have been described to
possess improved bioavailability and to be aﬄicted with less
side effects than geldanamycin derivatives, such as 17-AAG (55).
Nevertheless, also 17-AAG provided some treatment responses
in our in vitro system. It is interesting to note that the cell line
with lower expression of HSP90β–NCI-H295R—overall showed
higher responsiveness towardHSP90 inhibition.While these data
are too preliminary to suggest a marker of treatment response,
they inform that even low HSP90β expression levels are sufficient
to allow for a therapeutic impact of HSP90 inhibitors.
In current clinical practice, ACC patients not amendable
to surgery are treated with a combination of cytostatic drugs
including etoposide, doxorubicin, and cisplatin in combination
with the adrenolytic substancemitotane (56, 57). Recent evidence
has indicated that the combination of the HSP90 inhibitors
BIIB021 and CCT18159 with mitotane had limited additional
value (53). In contrast, following our current investigation, we
can provide a rational for a combined treatment of luminespib or
ganetespib with doxorubicin or etoposide as these combinations
demonstrated additive or synergistic effects, especially in NCI-
H295R cells. As the response rates of current chemotherapies are
generally low, combinations with further active substances could
be a strategy to improve therapeutic efficacy. At the same time,
drug related side effects, which are mostly dosage dependent,
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could be overcome by combination schemes with lower dosages
of the single agents.
Tumor heterogeneity is a well-appreciated basis of treatment
failure, because different tumor clones can bear diverse
functional characteristics including primary drug resistance.
Initiation of therapies increases selective pressure and may
drive evolution of a clone with pre-existing or newly acquired
functional properties that overcome therapeutic response. In
the present study, we have made usage of two different cells
lines and primary cultures from two different metastatic sites
of one ACC patient. In all instances, in vitro treatment with
N-terminal HSP90 inhibitors resulted in strong effects on cell
viability. Thereby, these findings—together with the widespread
expression of HSP90 in ACC samples—provide first indication
for a likely more general treatment response of ACC patients
toward HSP90 inhibitors. The MUC-1 cell line, which had been
derived from a metastasis of a patient pre-treated with several
cycles of EDP (48) was found to be less responsive to HSP90
inhibition. While these subtle differences in treatment response
are to be expected, it is interesting to note, that the cell lines also
differed with a more pronounced inhibition of cell proliferation
for MUC-1 cells while NCI-H295R cells were more prone to
undergo treatment related apoptosis.
A number of client proteins of HSP90, including
glucocorticoid receptor and kinases play an important role
in cancer signaling pathway (58). Similar to recent findings in
pituitary cells (39), treatment of adrenocortical cancer cell lines
with N-terminal HSP90 inhibitors decreased their glucocorticoid
receptor expression and additionally we observed a reduction
of cortisol secretion in NCI-H295R cells upon C-terminal and
N-terminal HSP90 inhibitor treatment at time points without
relevant effects on cell viability. We could further demonstrate
that, in line with their relevant anti-tumor activity, N-terminal
HSP90 inhibitors induce changes inmolecular pathways involved
in tumorigenesis. Among them, AKT and ERK1/2 pathways
have recently attracted attention as potential therapeutic targets
for ACC. Moreover, HSP90 inhibitors also affect AKT and
ERK1/2 pathways (59–62). Interestingly, we can demonstrate
that luminespib and ganetespib treatment leads to inhibition
of phosphorylated AKT and mTOR in both investigated cell
lines. Similarly, analysis of ERK1/2 pathway by western blot
further indicated a decrease of p-cRAF and p-MEK1/2 both in
NCI-H295R and MUC-1 cells. However, only in MUC-1 cells we
observed a reduction of p-ERK1/2 and p-RSK upon luminespib
and ganetespib treatment. It is prudent to speculate that these
differential molecular treatment responses could be related with
the observed differences in treatment response between both
cell lines.
We appreciate the limitation of the current study as the
functional analysis are based on two cell lines with further
supporting data from two individual ACC metastases from
one patient. Based on the recently reported progress in the
establishment of further human adrenocortical cells lines (63),
there is hope that future preclinical studies in the field can rely on
additional models that open the possibilities to study for further
individualized approaches.
In summary, new generation N-terminal HSP90 inhibitors
hold promise as agents with anti-tumor properties against
adrenocortical cancer cells. Furthermore, low expression of
HSP90β could be used as prognostic marker for ACC patients.
Following subsequent studies in appropriate preclinical models
could pave the way toward the introduction of N-terminal HSP90
inhibitors in the treatment of patients with ACC.
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